Unigene Initiates Phase I Clinical Study For Oral PTH

Unigene Laboratories, Inc. (OTCBB: UGNE http://www.unigene.com) has initiated a Phase I clinical study in the U.S. with its proprietary formulation of oral PTH for the treatment of osteoporosis. Twenty-four healthy postmenopausal women have been enrolled in the study, which is designed to assess product safety and measure PTH blood levels at varying doses.

More: continued here

Filed under: Bones on October 13th, 2008